Open House Originale Rabattverträge 2024-13 - Apremilast
Titre original de l'avis
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-13 - Apremilast
Score d'opportunité
Pourquoi ce score ?
Opportunité
46 / 100
Complexité
58 / 100
Facteurs de risque
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclude Open House rebate agreements for the active substance Apremilast.
- Provide supply of pharmaceutical products under uniform contract conditions.
Afficher le résumé complet
This is a German Open House pharmaceutical supply arrangement for Apremilast (CPV 33600000) led by Techniker Krankenkasse, with HEK, hkk and KKH listed as participating buyers. It is not a standard competitive award procedure: all eligible pharmaceutical companies meeting the stated conditions may join on uniform terms, with no exclusivity and no individual negotiations. The contract term runs from 01.01.2025 to 31.12.2026 at the latest, with possible earlier automatic end on patent/market exclusivity expiry. No contract value is provided in the structured data or XML. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents indicate a special deadline for 1 January 2025 inclusion.
Risques
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Applicant must be a pharmaceutical entrepreneur within the meaning of German medicines law for the offered medicinal products.
- Applicant must have its seat in the AMG scope, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product(s) or otherwise be entitled to place them on the market in its own name.
Acheteur
Localisation
Hamburg, DEU
Site web
Identifiant
992-80116-93
Activité
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2024-13 - Apremilast
Open House contract for Apremilast supply/rabatt agreements. Scope is nationwide in Germany. The lot concerns concluding uniform rebate contracts with eligible pharmaceutical companies for the active substance Apremilast. The lot information comes from structured data and XML notice.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Apremilast zu schließen.
Note sur la valeur
Afficher les données TED originales
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Apremilast zu schließen.
Détails de la procédure
- Date de publication
- 19 Nov 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 706936-2024
Documents (1)
Appels d'offres similaires
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Score d'opportunité
Pourquoi ce score ?
Opportunité
46 / 100
Complexité
58 / 100
Facteurs de risque
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications